Neurocrine Biosciences Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- SpaceX slides, tech stocks dip — what’s moving markets
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Neurocrine Biosciences (NBIX) Tops Q3 EPS by 75c
November 9, 2020 4:32 PM ESTNeurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $0.97, $0.75 better than the analyst estimate of $0.22. Revenue for the quarter came in at $258.5 million versus the consensus estimate of $283.04 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More